Testicular Cancer Incidence in Eight Northern European Countries: Secular and Recent Trends

Lorenzo Richiardi,1,4 Rino Bellocco,1 Hans-Olov Adami,1 Anna Torräng,1 Lotti Barlow,3 Timo Hakulinen,5 Mati Rahu,6,7 Aivars Stengrevics,8 Hans Storm,9 Steinar Tretli,10 Juozas Kurtinaitis,11 Jerzy E. Tyczynski,12 and Olof Akre2

1Department of Medical Epidemiology and Biostatistics and 2Clinical Epidemiology Unit, Department of Medicine, Karolinska Hospital, Karolinska Institutet, Centre for Epidemiology, National Board of Health and Welfare, Stockholm, Sweden; 3Unit of Cancer Epidemiology, CeRMS and Center for Oncologic Prevention, University of Turin, Italy; 4Finnish Cancer Registry, Helsinki, Finland; 5Department of Epidemiology and Biostatistics, Institute of Experimental and Clinical Medicine and National Centre for Excellence in Behavioural and Health Sciences, Tallinn, Estonia; 6Latvian Oncology Center, Riga, Latvia; 7Cancer Prevention & Documentation, Danish Cancer Society, Copenhagen, Denmark; 8Cancer Registry of Norway, Institute of Population-based Cancer Research, Oslo, Norway; 9Lithuanian Cancer Registry, Vilnius University Oncology Institute, Lithuania; and 10Unit of Descriptive Epidemiology, IARC, Lyon, France

Abstract

Objective: Striking geographic variation and marked increasing secular trends characterize the incidence of testicular cancer. However, it is not known whether these patterns have attenuated in recent years and whether they are similar for seminomas and nonseminomas, the two main histologic groups of testicular cancer.

Method: Cancer registry data, including 27,030 testicular cancer cases, were obtained from Denmark, Estonia, Finland, Latvia, Lithuania, Norway, Poland, and Sweden. Between 57 (Denmark) and 9 (Poland) years of registration were covered. Country-specific temporal trends were estimated, with focus on the last decade and seminomas and nonseminomas. Data from the Nordic countries were further analyzed using an age-period-cohort approach.

Results: Age-standardized incidence rates increased annually by 2.6% to 4.9% during the study period, with marginal differences between seminomas and nonseminomas. In the last decade, the increasing trend attenuated only in Denmark (annual change, −0.3%; 95% confidence interval, −1.5 to 0.9). In 1995, the highest and the lowest age-standardized incidence rates (per 105) were 15.2 in Denmark and 2.1 in Lithuania. Incidence rates (i.e., for all cancers and for seminomas and nonseminomas, separately) depended chiefly on birth cohort rather than on calendar period of diagnosis (although both birth cohort and period determined the Danish incidence rates).

Conclusions: Testicular cancer incidence is still increasing, with the exception of Denmark, and a large geographic difference exists. The increasing trend is mainly a birth cohort phenomenon also in recent cohorts. Temporal trends for seminomas and nonseminomas are similar, which suggests that they share important causal factors. (Cancer Epidemiol Biomarkers Prev 2004;13(12):2157–66)

Introduction

A secular increasing trend in the incidence of testicular cancer has been shown in Northern Europe (1-3), United Kingdom (4-6), Canada (7, 8), New Zealand (9), Australia (10), and the United States (11, 12), with the possible exception of Switzerland (13). An attenuation of the increasing trends was recently shown in Denmark (1), perhaps in the United States (12), but not in Canada (7), England or Wales (5). In the early 1990s, we carried out a collaborative study involving nine countries around the Baltic Sea and found that testicular cancer incidence doubled in 15 to 20 years, with an −10-fold geographic variation in incidence between participating countries (2). In the same study (14), as well as in studies of other populations (1, 7, 11, 12), the increasing trend seemed to be mainly a birth cohort phenomenon.

Despite efforts of analytic studies to investigate possible risk factors (mainly those acting early in life), causes of testicular cancer remain largely unknown and there are no satisfactory hypotheses to explain the trends in incidence nor in the geographic variations (15). Understanding testicular cancer etiology is complicated because two major histologic groups, seminomas and nonseminomas, peak in incidence at different ages: nonseminomas before 30 years of age and seminomas after age 30 (3, 6, 7, 10-12, 16). Hence, etiologic heterogeneity may exist between the two forms of testicular cancer. Some analytic studies have investigated seminomas and nonseminomas separately, but with conflicting results (17-31). Analogously, trend analyses have reported both similarities (11, 16) and differences (4, 7, 12) between the two histologic groups.

Comparing results from different countries is a valuable approach to understand whether the epidemic
of testicular cancer is abating and whether nonseminomas and seminomas have different temporal trends. We, therefore, updated our earlier collaborative study (2, 14), analyzing, in a standardized fashion, data on 27,000 testicular cancer cases diagnosed among men ages 15 to 64 years recorded up to 1998 to 2000 in cancer registries of eight Northern European countries. We investigated recent and secular trends in incidence, we disentangled between birth cohort and period effects, and we analyzed seminomas and nonseminomas separately.

Materials and Methods

Characteristics of Cancer Registries. The eight cancer registries included in our analyses are all population based, with different covered periods (Table 1). In Poland, compulsory cancer notification was established in 1952, but a satisfactorily complete nationwide registration is available from 1990. Although the Estonian Cancer Registry was founded formally in 1978, reliable centralized registration was present already in 1968. In Lithuania, a population-based registration of cancer covering the entire country started in 1964 and a cancer registry was established in 1975. Since 1990, the registration was considered complete enough to be included in the present study. For the other countries, we analyzed the entire available period of cancer registration, after excluding the first years, when some underreporting might have existed. We obtained data up to the last available year, which varied between 1998 and 2000 in different registries.

Detailed information on each of the eight cancer registries is available in publications of the IARC (32-34) and in national publications and Web sites (Denmark: http://www.cancer.dk/; Estonia: ref. 35; Finland: http://www.cancerregistry.fi/; Lithuania: http://www.is.lt/cancer_reg/; Norway: http://www.kreftregisteret.no/; Poland: ref. 36; Sweden: http://www.sos.se/epc/). A comprehensive comparison of the cancer registries of Denmark, Finland, Norway, and Sweden was published in 2000 (37).

Cancer and Population Data. Data on all cases of testicular cancer diagnosed among men ages 15 to 64 years were obtained from the cancer registries in the form of a list of anonymous individual records, including year of diagnosis, age at diagnosis, year of birth, and histologic codes. Data on histopathologic type of testicular cancer were, however, not available in the Polish Cancer Registry. Population data were provided in the form of 5-year age groups by Baltic countries, Finland, and Poland, whereas data in 1-year age groups were available in Denmark, Finland (since 1975), Norway, and Sweden. We report the total number of testicular cancer cases analyzed and the estimated male population by country (Table 1).

We used histologic information obtained from the registries to identify testicular cancers occurring in the germ cells and we classified them into seminomas and nonseminomas. A more detailed analysis of trends of different histologies was not feasible, because the cancer registries used different morphologic classifications with some changes over time (33, 35-37). Table 1 reports, for each country, the number of seminomas and nonseminomas analyzed.

Statistical Analyses. We analyzed the observed trends of age-standardized (world standard population; ref. 32) incidence of testicular cancer by country and histologic group. We estimated average annual changes and corresponding 95% confidence interval (95% CI) by fitting a linear regression model where the logarithm of the age-standardized incidence was assumed to be linearly dependent on calendar time. We also carried out Poisson regression models of age-adjusted (5-year age groups) incidence rates by calendar year. Because estimates from the Poisson and the linear regression models were similar, we decided to present average annual changes in the age-standardized incidence rate only (Table 2). We used linear splines, with a unique knot at year 1990, to better investigate late changes in the temporal distribution. Statistical analyses were conducted using STATA version 8.1.


Table 1. Characteristics of the study populations

<table>
<thead>
<tr>
<th>Country</th>
<th>Study period</th>
<th>Male population</th>
<th>All testicular cancers</th>
<th>Germ cell tumors</th>
<th>Seminomas</th>
<th>Nonseminomas</th>
</tr>
</thead>
<tbody>
<tr>
<td>Denmark</td>
<td>1943-1999</td>
<td>2.58</td>
<td>9,138</td>
<td>4,929 (54%)</td>
<td>3,833 (42%)</td>
<td></td>
</tr>
<tr>
<td>Norway</td>
<td>1955-1998</td>
<td>2.16</td>
<td>4,888</td>
<td>2,501 (51%)</td>
<td>2,383 (46%)</td>
<td></td>
</tr>
<tr>
<td>Sweden</td>
<td>1960-1999</td>
<td>3.93</td>
<td>5,830</td>
<td>3,094 (53%)</td>
<td>2,644 (45%)</td>
<td></td>
</tr>
<tr>
<td>Finland</td>
<td>1953-1999</td>
<td>2.49</td>
<td>1,842</td>
<td>931 (51%)</td>
<td>792 (43%)</td>
<td></td>
</tr>
<tr>
<td>Poland</td>
<td>1990-1998</td>
<td>18.57</td>
<td>4,388</td>
<td>163 (56%)</td>
<td>110 (38%)</td>
<td></td>
</tr>
<tr>
<td>Estonia</td>
<td>1968-1998</td>
<td>0.69</td>
<td>293</td>
<td>120 (46%)</td>
<td>100 (39%)</td>
<td></td>
</tr>
<tr>
<td>Lithuania</td>
<td>1990-1999</td>
<td>1.75</td>
<td>259</td>
<td>199 (51%)</td>
<td>168 (43%)</td>
<td></td>
</tr>
<tr>
<td>Latvia</td>
<td>1980-2000</td>
<td>1.16</td>
<td>392</td>
<td>199 (51%)</td>
<td>168 (43%)</td>
<td></td>
</tr>
</tbody>
</table>

*In 1995, in millions.

1All testicular cancers occurring in patients aged between 15 and 64 years at diagnosis, including germ cell tumors, non-germ cell tumors, and testicular tumors with unspecified histology.

Seminomas and nonseminomas were defined according to the codes/recodes of the following classifications: Denmark, modified ICD-7 (67); Norway, Manual of Tumor Nomenclature and Coding (68) and ICD for Oncology-2 (ICDO-2) (since 1990) (69); Sweden, C24 (WHO/HS/CANC/24.1); Finland, Manual of Tumor Nomenclature and Coding (70); Estonia, ICDO-2 (69); Lithuania, ICDO-2 (69); Latvia, ICDO-2 (69).

1Not applicable. Information on histology was not available in the Polish Cancer Registry.
Table 2. Average annual change in age-standardized (world standard population) incidence of testicular cancer by country, period, and histological type

<table>
<thead>
<tr>
<th>Country</th>
<th>Histological group</th>
<th>Entire period</th>
<th>&lt;1990</th>
<th>&gt;1990</th>
<th>Incidence in 1995</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>&lt;1990 (95% CI)</td>
<td>&gt;1990 (95% CI)</td>
<td></td>
<td>Observed (95% CI)</td>
</tr>
<tr>
<td>Denmark</td>
<td>All²</td>
<td>2.6 (2.4-2.8)</td>
<td>2.8 (2.7-3.0)</td>
<td>-0.3 (-1.5 to 0.9)</td>
<td>15.0 (14.6-16.2)</td>
</tr>
<tr>
<td></td>
<td>Seminomas</td>
<td>2.4 (2.2-2.7)</td>
<td>2.6 (2.3-2.8)</td>
<td>0.9 (-1.2 to 2.9)</td>
<td>8.3 (7.3-8.7)</td>
</tr>
<tr>
<td></td>
<td>Nonseminomas⁴</td>
<td>3.4 (3.1-3.6)</td>
<td>3.9 (3.6-4.3)</td>
<td>-3.5 (-5.8 to -1.2)</td>
<td>6.2 (6.2-7.5)</td>
</tr>
<tr>
<td>Norway</td>
<td>All</td>
<td>3.0 (2.7-3.3)</td>
<td>3.0 (2.6-3.4)</td>
<td>2.9 (0.5-5.2)</td>
<td>11.3 (12.3-14.8)</td>
</tr>
<tr>
<td></td>
<td>Seminomas</td>
<td>2.6 (2.2-3.0)</td>
<td>2.6 (2.1-3.0)</td>
<td>2.7 (0.0-5.4)</td>
<td>4.7 (5.7-7.1)</td>
</tr>
<tr>
<td></td>
<td>Nonseminomas</td>
<td>3.7 (3.2-4.1)</td>
<td>3.7 (3.2-4.3)</td>
<td>2.8 (-0.6 to 6.1)</td>
<td>6.3 (5.9-7.7)</td>
</tr>
<tr>
<td>Sweden</td>
<td>All</td>
<td>3.2 (3.0-3.5)</td>
<td>3.3 (3.0-3.7)</td>
<td>2.5 (1.1-3.9)</td>
<td>8.6 (8.3-9.9)</td>
</tr>
<tr>
<td></td>
<td>Seminomas</td>
<td>3.1 (2.8-3.4)</td>
<td>2.8 (2.3-3.2)</td>
<td>5.0 (3.4-6.7)</td>
<td>5.3 (4.5-5.1)</td>
</tr>
<tr>
<td></td>
<td>Nonseminomas⁴</td>
<td>3.0 (3.0-3.9)</td>
<td>4.0 (3.4-4.5)</td>
<td>0.0 (-2.3 to 2.4)</td>
<td>3.2 (4.0-4.8)</td>
</tr>
<tr>
<td>Finland</td>
<td>All</td>
<td>3.9 (3.4-4.3)</td>
<td>3.8 (3.2-4.4)</td>
<td>4.6 (1.4-7.9)</td>
<td>3.0 (2.8-3.5)</td>
</tr>
<tr>
<td></td>
<td>Seminomas</td>
<td>3.1 (2.4-3.7)</td>
<td>3.0 (2.1-3.8)</td>
<td>3.8 (-0.9 to 8.6)</td>
<td>1.1 (1.1-1.5)</td>
</tr>
<tr>
<td></td>
<td>Nonseminomas</td>
<td>6.0 (5.2-6.8)</td>
<td>6.3 (5.3-7.4)</td>
<td>3.3 (-2.3 to 9.0)</td>
<td>1.7 (1.3-2.0)</td>
</tr>
<tr>
<td>Poland</td>
<td>All</td>
<td>4.3 (2.4-6.3)</td>
<td>—</td>
<td>—</td>
<td>2.6 (2.6-2.8)</td>
</tr>
<tr>
<td></td>
<td>Seminomas</td>
<td>3.2 (1.7-4.7)</td>
<td>3.2 (1.0-5.4)</td>
<td>3.1 (-4.0 to 10)</td>
<td>5.3 (2.6-3.3)</td>
</tr>
<tr>
<td></td>
<td>Nonseminomas</td>
<td>2.4 (0.3-4.5)</td>
<td>2.0 (-1.0 to 5.0)</td>
<td>4.4 (-5.4 to 14)</td>
<td>1.9 (0.9-1.8)</td>
</tr>
<tr>
<td>Lithuania</td>
<td>All</td>
<td>4.7 (0.3-9.1)</td>
<td>7.5 (3.9-11)</td>
<td>2.9 (0.9 to 15)</td>
<td>2.6 (1.0-1.8)</td>
</tr>
<tr>
<td></td>
<td>Seminomas</td>
<td>4.9 (0.0-10.0)</td>
<td>—</td>
<td>—</td>
<td>1.6 (1.8-2.4)</td>
</tr>
<tr>
<td></td>
<td>Nonseminomas</td>
<td>6.3 (-1.2 to 14)</td>
<td>—</td>
<td>—</td>
<td>1.1 (0.9-0.8)</td>
</tr>
<tr>
<td>Latvia</td>
<td>All</td>
<td>7.8 (-2.8 to 18)</td>
<td>—</td>
<td>—</td>
<td>1.3 (0.6-1.0)</td>
</tr>
<tr>
<td></td>
<td>Seminomas</td>
<td>4.2 (2.1-6.2)</td>
<td>3.0 (-1.6 to 7.6)</td>
<td>5.3 (0.7-10)</td>
<td>2.3 (2.6-3.0)</td>
</tr>
<tr>
<td></td>
<td>Nonseminomas⁴</td>
<td>4.0 (-0.3 to 8.4)</td>
<td>-3.2 (-12 to 6.1)</td>
<td>11 (1.9-20)</td>
<td>0.7 (0.9-1.6)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6.8 (2.3-11)</td>
<td>16 (7.7-25)</td>
<td>-2.8 (-12 to 6.0)</td>
<td>1.5 (0.9-1.5)</td>
</tr>
</tbody>
</table>

NOTE: Observed and estimated incidence (per 100,000) in 1995.

*Estimated with a linear regression model using age-standardized incidence and linear splines with one knot at 1990.

Two-sided test for difference in linear trend before and after 1990: P < 0.05.
Results

Trend Analyses. The age-standardized incidence of testicular cancer increased over time in all countries, although patterns for the three Baltic countries are less clear due to the small number of cases (Fig. 1). The increasing trend was evident both for seminomas and nonseminomas. The highest incidence was found in Denmark followed by Norway and Sweden.

Estimated incidence and average annual changes by country and histologic group are summarized in Table 2. In 1995, highest and lowest age-standardized incidences

![Figure 1. Age-standardized (world standard population) incidence of testicular cancer by year of diagnosis, country, and histological type.](image-url)
were 15.4 per 100,000 (95% CI, 14.6-16.2) in Denmark and 2.1 per 100,000 (95% CI, 1.8-2.4) in Lithuania. During the entire period of analysis, the lowest increase in incidence was found in Denmark (2.6%; 95% CI, 2.4-2.8), whereas the annual change was above 3% in all other countries. We found no major differences between seminomas and nonseminomas.

When trend analyses were focused on the last decade (after 1989), we found evidence of a leveling off of incidence in Denmark, where the estimated annual change was -0.3% (95% CI, -1.5 to 0.9). Trend appearances did not change substantially in the other countries during the last decade, with the exception of Sweden, where we found a markedly stronger annual change.
change for seminomas (5.0%; 95% CI, 3.4-6.7) than for nonseminomas (0.0%; 95% CI, -2.3 to 2.4).

Age-Period-Cohort Analyses. We plotted age-specific rates by birth cohort for each of the four Nordic countries and different histologic entities (Fig. 2). For almost any birth cohort, the highest incidences were found in the age groups 25 to 29 for nonseminomas and 30-34/35-39 for seminomas. Rates increased with successive birth cohorts among all age groups and countries but Denmark, where the increase leveled off in the most recent cohorts. For instance, incidence of nonseminomas peaked in the 1970 cohort among those ages 15 to 19 and in the 1960 cohort among those ages 20 to 24 and 25 to 29 years.

Results of the goodness-of-fit tests for the partial APC models are reported in Table 3. The age-cohort model fitted the observed counts in Finland for all testicular cancers and nonseminomas, in Norway for all histologic entities, and in Sweden for all testicular cancers and nonseminomas. The age-only model fitted the data in none of the countries. When we analyzed seminomas in Norway, and Sweden, but not Finland, as shown by contrasts below unity for those born in the 1935 cohort in Denmark and Norway, and for those born in the 1930 cohort in Sweden. This means that in Denmark, for instance, the ratio between the relative risks for the cohorts 1940 and 1935 was smaller than the ratio between the relative risks for the cohorts 1935 and 1930. In Denmark, Norway, and Sweden, there was an acceleration in the increasing in incidence rate, indicated by contrast estimates and confidence intervals above unity, among men born around 1950 (1940 in Sweden). In Denmark, the increasing trend in incidence leveled off again among men born in the 1965 and 1970 cohorts.

Seminomas and nonseminomas had similar patterns in all four countries (Fig. 4). Particularly in Denmark and Norway, the war time effect on incidence was evident for both histologic entities.

The analysis on periods did not suggest relevant nonlinear effects, with two main exceptions (Fig. 3). First, the increase in incidence of testicular cancer attenuated in Denmark starting from the 1980 to 1984 period. This pattern was evident both for seminomas and nonseminomas, whereas it did not apply to non germ cell tumors. Due to these specific nonlinear period effects, we fitted Danish data with separate models for men diagnosed before 1980 and those diagnosed after that. The age-cohort models fitted the observed counts for all testicular cancers (before 1980, $P = 0.18$; after 1980, $P = 0.63$), for nonseminomas (before 1980, $P = 0.59$; after 1980, $P = 0.12$), and for seminomas (before 1980, $P = 0.08$; after 1980, $P = 0.67$). The second exception regards Finland, where we found attenuation of the increasing trend in incidence in two consecutive periods between 1975 and 1984. This nonlinear period effect was confined to nonseminomas.
Figure 3. Estimable birth cohort and period effects on incidence of testicular cancer (mutually and age adjusted) and corresponding 95% CIs, by country (results for older Finnish birth cohorts are not reported because of instability of the estimates). Birth cohorts and periods are denoted by their middle year. Contrasts are second differences between successive birth cohorts or periods on a logarithmic scale.
Discussion

Methodologic Considerations. We analyzed temporal trends in incidence of testicular cancer in eight populations, allowing direct assessment of the consistency of trend patterns. The reliability of our results depends on the quality of cancer registration in each of the participating countries. Testicular cancer occurs in young men and is generally easily diagnosed, suggesting that virtually all testicular tumors in the population are clinically detected and histopathologically verified. Furthermore, the completeness of the registry data in this study is high, and we have no reasons to believe that testicular cancer registration has been worse than for other cancers. However, changes in completeness of registration over time may have artificially influenced temporal trends to some extent. The consistency of our findings between countries and the general lack of nonlinear period effects suggest that such artifact had marginal, if any, effect on the registration of testicular cancer.

A certain degree of misclassification between seminomas and nonseminomas as well as between germ cell tumors and non-germ cell tumors has most likely occurred. If the level of misclassification changed over time, separate analysis of the histologic subgroups may have produced altered trend appearances. There are some particular periods in time when relevant changes occurred. At the end of the 1970s, the British Testicular Tumor Panel (41) and the WHO (42) introduced standards in the classification of testicular cancers. In the same years, advances in treatment, due to the introduction of cisplatinum-based chemotherapy for nonseminomas, increased the clinical importance of a precise histologic definition. With some possible exceptions, we did not find nonlinear period effects suggesting a relevant influence on temporal trends of changes either in histologic classifications or in pathologists’ practice. These changes have affected to a greater extent the distribution of the different types of nonseminomas (choriocarcinomas, teratomas, and yolk sac tumors), rather than the proportion of the three main subgroups: seminomas, nonseminomas, and non-germ cell tumors. Another source of possible misclassification are lymphomas of the testis coded as testicular cancers. However, we restricted analyses to men ages <65 years at diagnosis, whereas lymphomas occur mainly at older ages.

We did not attempt to calibrate the different classifications used in different registries. Thus, although it is

Figure 4. Estimable birth cohort effects on incidence of testicular cancer (adjusted for age and period) by country and histological type (results for older Finnish birth cohorts are not reported because of instability of the estimates). Birth cohorts are denoted by their middle year. Contrasts are second differences between successive birth cohorts on a logarithmic scale.
possible to interpret geographic variations in incidence of testicular cancer as a single entity, similar comparisons are less meaningful when seminomas and nonseminomas are considered separately. For example, in the Danish Cancer Registry, the modified International Classification of Diseases (ICD-7) codes include chorionar- cinomas and some types of non-germ cell tumors, as cancers occurring in Sertoli cells, in the same category. Translation of codes to an internally harmonizing classification would have lead to losses of information, and we therefore chose to prioritize comparability within countries over time, rather than between countries.

Main Findings. Our first main finding is that the incidence of testicular cancer is still increasing, and we ascribed this trend mainly to a birth cohort phenomenon in the Nordic countries. Moreover, the large geographic variation in incidence among countries around the Baltic Sea estimated in 1980 (2) is still present at the end of 1990s. In other words, the descriptive epidemiologic features of testicular cancer have not been changing substantially in recent times. Denmark is an exception, with its nonlinear period effects and its attenuated incidence trend from the early 1990s onwards. These results confirm findings of a previous Danish study based on incidence data up to 1996 (1). Relevant nonlinear period effects, indicating an attenuation of the increasing trend, have also been detected recently in the US (12) but not in the Canadian population (7).

In the search for risk factors that might explain the observed temporal trends, events early in life have been in focus. A causal role of such factors is supported by several pieces of evidence, including (i) testicular cancer peaks in incidence at early adulthood and may be already present at young ages; (ii) cancer in situ of the testis, a precursor of virtually all germ cell tumors, is believed to be generated in utero (43); (iii) the risk of testicular cancer is associated with the cohort of birth; analyses of Danish and Norwegian data using a frailty model fit with the hypothesis that testicular cancer occurs in a small proportion of men in the population, who acquire first germ cell damages early in life (44); and (iv) migration studies showed that men emigrating from countries with a high (or low) incidence of testicular cancer emigrating from a country with a low (or high) incidence maintained their original risk (45, 46), irrespective of the age at immigration (45). Analytic studies investigating indicators of specific exposures acting prenatally or perinatally (possibly endogenous or exogenous estrogens 47), such as birth weight, birth order, maternal age, gestational age, have, however, not produced consistent findings (19-23, 25,27,28,30, 48-52). Cryptorchidism is associated with an increased risk of testicular cancer, but the etiologic fraction is only around 10%, and cannot thus explain the observed temporal trends (53). Maternal factors during pregnancy, in particular smoking (54, 55) and perhaps diet, deserve further investigation because they have changed over time. Moreover, subfertility has been linked to the risk of testicular cancer and the understanding of the causal pathway underlying this association may help in the search and study of candidate exposures (29, 56-58).

The nonlinear period effects in Denmark (and in Finland for nonseminomas) may suggest that postnatal exposures also affect the risk for testicular cancer, perhaps acting as tumor promoters. Early age at puberty (18, 20, 57, 59), adult tallness (60-62), sedentary behavior (57, 63), and consumption of fats, milk, and dairy products (31, 64-66) all have been associated with testicular cancer risk. However, for none of these factors has a causal association with testicular cancer been convincingly documented. The nonlinear period effect is an unexpected observation, for which we do not have a biological explanation.

A novel finding from the present study is that the temporal trends for seminomas and nonseminomas are similar, suggesting that the unknown cause(s) of the increasing trends are shared by the two main histologic forms. It has been debated whether etiologic heterogeneity exists and recent analytic studies included, whenever possible, separate analyses of seminomas and nonseminomas. In many instances, they have reported heterogeneities in some of the characteristics but no factor has been consistently associated with only one of the main histologic types (17-31). Reasons for inconsistent results might be a general problem of limited sample size to detect interactions in most of the studies, but also a true lack of an etiologic heterogeneity between the two histologic groups. Thus, although there is difference in age at peak in incidence between the two histologic forms, it seems that studies on testicular cancer etiology should primarily aim at testing candidate exposures responsible for increasing in incidence rather than at assessing etiologic heterogeneities.

In conclusion, in eight Northern European populations testicular cancer incidence is still increasing, with the possible exception of Denmark, and large geographic variations persist. APC analyses in Nordic countries revealed that the increasing trend is mainly a birth cohort phenomenon also in recent cohorts (with significant calendar period effects in Denmark). Finally, temporal trends for the two major histologic types of testicular cancer, seminomas and nonseminomas, are similar, which suggests that they have important causal factors in common.

Acknowledgment
We thank Kaja Rahu for her help in data management.

References
Testicular Cancer Incidence in Eight Northern European Countries: Secular and Recent Trends

Lorenzo Richiardi, Rino Bellocco, Hans-Olov Adami, et al.


Updated version
Access the most recent version of this article at:
http://cebp.aacrjournals.org/content/13/12/2157

Cited articles
This article cites 53 articles, 6 of which you can access for free at:
http://cebp.aacrjournals.org/content/13/12/2157.full#ref-list-1

Citing articles
This article has been cited by 14 HighWire-hosted articles. Access the articles at:
http://cebp.aacrjournals.org/content/13/12/2157.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.